From:  Assessment of cardiovascular disease-associated mortality risk among early-stage breast cancer patients

 Univariate and multivariable Fine-Gray competing risk analysis for CSM in patients with BC.

CharacteristicsCSM
Univariate analysisMultivariable analysis
SHR (95% CI)P valueSHR (95% CI)P value
Age
18–49Reference
50–592.45 (2.03–2.95)< 0.0012.37 (1.96–2.86)< 0.001
60–696.47 (5.45–7.68)< 0.0016.01 (5.06–7.14)< 0.001
70–8525.60 (21.71–30.19)< 0.00119.37 (16.37–22.91)< 0.001
Race
WhiteReference
Black1.25 (1.16–1.35)< 0.0011.37 (1.27–1.48)< 0.001
Other0.56 (0.50–0.62)< 0.0010.73 (0.65–0.81)< 0.001
Marital status
MarriedReference
Unmarried2.36 (2.24–2.48)< 0.0011.59 (1.51–1.68)< 0.001
T (%)
T1Reference
T21.13 (1.07–1.19)< 0.0011.32 (1.24–1.40)< 0.001
T30.87 (0.77–0.98)0.0031.23 (1.08–1.40)0.002
T41.36 (1.16–1.59)< 0.0011.60 (1.35–1.89)< 0.001
N (%)
N0Reference
N10.80 (0.75–0.86)< 0.0011.12 (1.04–1.20)0.002
N20.87 (0.77–0.98)0.0221.29 (1.14–1.47)< 0.001
N30.96 (0.83–1.12)0.6101.34 (1.15–1.57)< 0.001
ER (%)
NegativeReference
Positive1.18 (1.09–1.26)< 0.0010.96 (0.87–1.06)0.386
PR (%)
NegativeReference
Positive1.05 (0.99–1.11)0.1000.97 (0.90–1.04)0.364
HER2 (%)
NegativeReference
Positive0.73 (0.67–0.79)< 0.0011.01 (0.93–1.10)0.800
Grade (%)
ⅠReference
Ⅱ0.95 (0.90–1.01)0.1101.01 (0.95–1.07)0.804
Ⅲ0.80 (0.74–0.85)< 0.0011.08 (1.00–1.17)0.053
Ⅳ0.55 (0.30–0.98)0.0440.72 (0.40–1.31)0.284
Surgery (%)
BCTReference
ME1.02 (0.97–1.07)0.4400.90 (0.85–0.96)< 0.001
Radiation (%)
No/UnknownReference
Yes0.56 (0.54–0.59)< 0.0010.64 (0.61–0.68)< 0.001
Chemotherapy (%)
No/UnknownReference
Yes0.34 (0.32–0.36)< 0.0010.59 (0.55–0.64)< 0.001
Return to article view

BC: breast cancer; BCT: breast-conserving therapy; CI: confidence intervals; CSM: cardiovascular-specific mortality; ER: estrogen receptor; HER2: human epidermal growth factor receptor 2; ME: mastectomy; PR: progesterone receptor; SHR: sub-distribution hazard ratio.